These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. L-tryptophan in the treatment of levodopa induced psychiatric disorders. Miller EM; Nieburg HA Dis Nerv Syst; 1974 Jan; 35(1):20-3. PubMed ID: 17894051 [TBL] [Abstract][Full Text] [Related]
3. Tryptophan malabsorption in levodopa-treated parkinsonian patients. Effect of tryptophan on mental disturbances. Lehmann J Acta Med Scand; 1973; 194(3):181-9. PubMed ID: 4746526 [No Abstract] [Full Text] [Related]
5. Biochemical assessment of niacin deficiency among carcinoid cancer patients. Shah GM; Shah RG; Veillette H; Kirkland JB; Pasieka JL; Warner RR Am J Gastroenterol; 2005 Oct; 100(10):2307-14. PubMed ID: 16181385 [TBL] [Abstract][Full Text] [Related]
6. [Reports on mental disorders in Parkinson disease in relation to treatment with L-dopa]. Agostino R; Fabri S Riv Neurobiol; 1983; 29(4):577-84. PubMed ID: 6678478 [No Abstract] [Full Text] [Related]
7. Parkinsonism, levodopa, and intelligence. Loranger A; Sweet RD; Goodell H; McDowell F Int J Neurol; 1975; 10(1-4):276-81. PubMed ID: 1181314 [No Abstract] [Full Text] [Related]
8. [Mental disorders in patients with Parkinson's disease treated with L-dopa]. Piccirilli M; Piccinin GL Clin Ter; 1981 Jun; 97(5):473-9. PubMed ID: 7273659 [No Abstract] [Full Text] [Related]
9. Ondansetron, a 5-HT3 antagonist for visual hallucinations and paranoid delusional disorder associated with chronic L-DOPA therapy in advanced Parkinson's disease. Zoldan J; Friedberg G; Weizman A; Melamed E Adv Neurol; 1996; 69():541-4. PubMed ID: 8615178 [No Abstract] [Full Text] [Related]
10. Low plasma tryptophan in carcinoid patients is associated with increased urinary cortisol excretion. Tanke MA; Kema IP; Dijck-Brouwer J; Doornbos B; De Vries EG; Korf J Psychoneuroendocrinology; 2008 Oct; 33(9):1297-301. PubMed ID: 18722719 [TBL] [Abstract][Full Text] [Related]
11. Psychiatric symptoms in carcinoid syndrome. Trivedi S J Indian Med Assoc; 1984 Aug; 82(8):292-4. PubMed ID: 6491341 [No Abstract] [Full Text] [Related]
12. Involvement of serotonin in clinical features of Parkinson's disease and complications of L-DOPA therapy. Melamed E; Zoldan J; Friedberg G; Ziv I; Weizmann A Adv Neurol; 1996; 69():545-50. PubMed ID: 8615179 [No Abstract] [Full Text] [Related]
13. "Panic attacks" in Parkinson's disease. A long-term complication of levodopa therapy. Vázquez A; Jiménez-Jiménez FJ; García-Ruiz P; García-Urra D Acta Neurol Scand; 1993 Jan; 87(1):14-8. PubMed ID: 8424307 [TBL] [Abstract][Full Text] [Related]
14. A comparative study of bromocriptine and levodopa in Parkinson's disease. Duvoisin RC; Mendoza MM; Yahr MD Adv Biochem Psychopharmacol; 1980; 23():271-5. PubMed ID: 7395618 [No Abstract] [Full Text] [Related]